Tim is CEO and member of the Board of Directors of AgomAb. Prior to that, Tim held the position of VP Corporate Development at AM-Pharma where he and the team executed a Phase IIb trial in patients with sepsis-associated acute kidney injury, secured a $600M option-to-buy deal with Pfizer and raised $133M in a private financing round. Prior to AM-Pharma, Tim was a Senior Associate at Aescap Venture, a VC fund investing in European medical companies. Tim is a Henri Termeer Fellow and holds an executive MBA from IMD, where he was named Valedictorian. He earned a Science and Innovation Masters and a Drug Innovation Masters from Utrecht University.

Paolo is a growth factor expert and the CSO of AgomAb. He spent several years conducting research at the National Cancer Institute, National Institutes of Health in Bethesda, Maryland, in the laboratory that discovered that MET is the HGF receptor in the early 1990s. Since he returned to Italy, he has been directing a translational medicine lab at the University of Torino Medical School, exploring new therapeutic strategies in both oncology and regenerative medicine. In collaboration with argenx, Paolo’s team generated a set of MET-agonistic, HGF-mimetic antibodies with powerful anti-fibrotic and pro-regenerative potential. This discovery led to the foundation of AgomAb. Paolo holds a MSc in Biology from the University of Milano, a PhD in Cell Sciences and Technologies from the University of Torino and a Clinical Pathology Specialty Diploma from the University of Torino.

Torsten is the CDO at AgomAb and brings an extensive expertise in developing antibodies and antibody-based drugs with more than 20 years in the pharmaceutical industry. He has a successful track record of progressing 10 antibody products from preclinical research to clinical development, including two (Blincyto and Cablivi) that obtained marketing authorization. Prior to joining AgomAb, Torsten was the Co-Founder and Chief Development Officer at argenx, overseeing various aspects of drug development. Between 2003 and 2008, he was at Ablynx, where he was responsible for pharmacology, toxicology, bioanalytics and CMC as well as early clinical development. Torsten holds a PhD in Biochemistry from the University of Tübingen, Germany.

Philippe joined AgomAb as CMO in 2021. He was previously the CMO at Genkyotex where he led the company’s clinical development activities for the treatment of several fibrotic disorders in the liver, lung, and kidney. Prior to this role, Philippe co-founded Genexion, which was focused on developing early-stage clinical assets in partnership with emerging biotech companies. Before this, Philippe was Medical Director at EMD Serono’s Swiss and US offices, where he was involved with the global development of several biologics. In particular, he led the late-stage clinical development of Raptiva, achieving the first marketing authorization in Europe for a biological therapy targeting psoriasis. Philippe received an MD in Medicine from Lausanne University Medical School and was a postdoctoral researcher at Harvard University Medical School and the Division of Hypertension at Lausanne University.

Paul joined AgomAb in 2021 as Chief Business Officer. Prior to AgomAb, he was Head of Corporate Development at Galapagos from 2016-2021. In this role, he led all major transactions, investments, licensing and M&A activities for the company. Most notably, he was a key negotiator for Galapagos’ transformative $5bn strategic collaboration with Gilead Sciences. From 2013-2016, he worked at boutique investment bank Kempen & Co in Amsterdam, where was responsible for broking and dealing of European pharma & biotech stocks to institutional investors in Europe and the US. In addition, Paul is a member of the Board of Directors at Fibrocor Therapeutics (Toronto, Canada). Paul studied medicine and holds a PhD in Gynaecological Oncology from the Erasmus University Medical Centre in Rotterdam, The Netherlands.

Tolga joined AgomAb as CFO in 2021 and brings over 25 years of strategic financial management and corporate structuring experience. He previously held board level roles as Chief Financial Officer and Chief Operating Officer at F-star Therapeutics where he was directly involved in a number of licensing and option-to-buy transactions with companies such as Merck, AbbVie and Denali Therapeutics, as well as preparing the business to become a clinical-stage, NASDAQ-listed biotech company. Prior to this, he was the Director of Corporate Development at FTSE-100 specialty chemicals and API company Johnson Matthey, and previously worked in various valuation and transaction advisory roles at Andersen. Tolga holds an MA in Economics from the University of Cambridge and is a qualified Chartered Accountant.